Sonoma pharmaceuticals reports first quarter 2023 financial results

Revenue increase of 73% from q4 22 and 8% from q1 22 reduction of net loss by $0.2 million or 19% versus q1 22 reduction of ebitdas loss by $0.2 million or 23% versus q1 22 reduction in net loss per share of 44% versus q1 22 boulder, co / accesswire / august 11, 2022 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, today announced financial results for its first fiscal quarter ended june 30, 2022. "our first quarter results reflect our continued prioritization of growth and profitability," said amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking